4Bio Partners, which trades as 4BIO Capital, is a London-headquartered venture capital firm that invests exclusively in the advanced-therapies sector. It backs early-stage life-science companies developing cell and gene therapies,…Read full bio
No exits recorded yet.
1 fund tracked, 9 portfolio companies (9 active · 0 realized). Verified weekly from public filings and deal announcements.
4BIO Partners (4BIO Capital) is one of the few venture capital firms investing exclusively in advanced therapies with approximately $300 million plus of assets under management as of December 2024 across Ventures II and Ventures III (Ventures III is 2023 vintage, with the Development Bank of Japan joining Ventures III in January 2024), headquartered in London. The firm was founded in 2015 as a specialist VC focused on advanced therapies and operates as 4BIO Partners LLP, FCA-regulated.
4BIO Partners deploys capital through approximately three funds (4BIO Ventures I, II, III), targeting early-stage venture capital exclusively in advanced therapeutics addressing high unmet medical need. Sector focus spans cell and gene therapy, RNA-based therapeutics, targeted therapies, microbiome and broader advanced and emerging biotech modalities. Geographic deployment is global across the US, UK and Europe, London-based. The platform aims to take advanced therapy modalities (cell, gene, RNA) mainstream.
Recent realised exits include an antibody-drug conjugate and biotech acquisition (2024). Recent investments include oncology viral immunotherapy Series A (2025), gene therapy Series A (2024-2025) and radiopharmaceutical and targeted therapy Series A (2024-2025). The platform continues active deployment of Ventures III across the advanced therapeutics mandate. Detailed buyer names and multiple data available on Pro at €49/month.
Other private equity firms tracked on GP Intel.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in